Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma

Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma

Summary: Oral cavity squamous cell carcinoma (OCSCC) is a prevalent surgically treated subset of head and neck cancer with frequent recurrence and poor survival. Immunotherapy has demonstrated efficacy in recurrent/metastatic head and neck cancer. However, whether antitumor responses could be foster...

Full description

Bibliographic Details
Main Authors: Hannah M. Knochelmann, Joshua D. Horton, Sixue Liu, Kent Armeson, John M. Kaczmar, Megan M. Wyatt, Mary S. Richardson, Shirley H. Lomeli, Ying Xiong, Evan M. Graboyes, Eric J. Lentsch, Joshua D. Hornig, Judith Skoner, Seth Stalcup, Maria V. Spampinato, Elizabeth Garrett-Mayer, Elizabeth C. O’Quinn, Cynthia D. Timmers, Martin J. Romeo, John M. Wrangle, M. Rita I. Young, Mark P. Rubinstein, Terry A. Day, Roger S. Lo, Chrystal M. Paulos, David M. Neskey
Format: Article
Language:English
Published: Elsevier 2021-10-01
Series:Cell Reports Medicine
Subjects:
neoadjuvant
PD-1 therapy
nivolumab
neoadjuvant immunotherapy
oral cavity cancer
head and neck cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2666379121002883

Internet

http://www.sciencedirect.com/science/article/pii/S2666379121002883

Similar Items